Economic Atlas
Companies/Recursion Pharmaceuticals, Inc.
Company profile

Recursion Pharmaceuticals, Inc.

NASDAQ: RXRX · Healthcare · Biotechnology
PublicHQ Salt Lake City, UT · Salt LakeCIK 0001601830Reports USD
#384 of 1,422 Healthcare companies by revenue70th-percentile growth
EA Score
54D
Revenue TTM
$66.3M
Rev growth YoY (TTM)
+11.0%
Net income (FY)
-$644.8M
Employees
600
as of 2026-08-09
Market cap
$1.7B
as of 2026-08-09

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$74.7M$74.7M2025
Net income-$644.8M-$644.8M2025
Operating income-$648.1M-$648.1M2025
Total assets$1.5B$1.5B2025
Liabilities$343.3M$343.3M2025
Equity$1.1B$1.1B2025

Revenue trend

FY2021 – FY2025 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
License and Service99%
Grant1%
By geography
UNITED STATES100%
The read

What is Recursion Pharmaceuticals, Inc.’s revenue?

Recursion Pharmaceuticals, Inc. booked $74.7M in FY2025 revenue, growing 27% year over year — faster than most Healthcare companies we track, at a -863.4% net margin.

Peers · Healthcare
Interpharm Holdings, Inc.——Lifecore Biomedical, Inc.66BAbCellera Biologics Inc.54DHealwell AI Inc.60COmeros Corporation65BAssembly Biosciences, Inc.63C
Neighbors
Salt Lake →
Extra Space Storage Inc.$129.5M67BZions Bancorporation, National Association$529.0M57CHealthEquity, Inc.$1.3B82B+Merit Medical Systems, Inc.$1.5B83B+Rest Ez Inc.$0——PROG Holdings, Inc.$2.4B72B
Key facts
CEONajat Khan
SectorHealthcare
IndustryBiotechnology
HeadquartersSalt Lake City, UT
ExchangeNASDAQ: RXRX
Employees600
IPO date2021-04-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.